9 studies found for:    E2609
Show Display Options
Rank Status Study
1 Completed Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White Subjects
Condition: Healthy Subjects
Interventions: Drug: E2609;   Drug: Placebo
2 Completed Evaluation of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of E2609 in Healthy Subjects
Condition: Healthy
Interventions: Drug: E2609;   Drug: Placebo
3 Completed An Open-label, Single Dose Study to Determine the Metabolism and Elimination of [14C]E2609 in Healthy Male Subjects
Condition: Metabolism and Elimination
Intervention: Drug: E2609
4 Completed Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)
Condition: Alzheimer's Disease
Interventions: Drug: E2609;   Drug: Placebo for E2609
5 Completed A Study to Evaluate the Effects of E2609 on QTc Interval in Healthy Subjects
Condition: Healthy Subjects
Interventions: Drug: Placebo;   Drug: E2609;   Drug: Moxifloxacin
6 Completed An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption
Condition: Alzheimer's Disease
Intervention: Drug: E2609
7 Completed A 3-Part, Open-Label, Drug-Drug Interaction Study of Concomitant Administration of E2609 With Itraconazole, Rifampin, Digoxin, or Donepezil
Condition: Healthy Subjects
Interventions: Drug: E2609;   Drug: itraconazole;   Drug: rifampin;   Drug: digoxin;   Drug: donepezil
8 Recruiting Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease
Conditions: Alzheimer Disease;   Dementia, Alzheimer Type
Interventions: Drug: E2609;   Drug: Placebo
9 Completed Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Subjects and an Elderly Cohort
Condition: Alzheimer's Disease
Interventions: Drug: Drug: E2609;   Drug: Placebo

Indicates status has not been verified in more than two years